ArticleBiomedical optics express2025
Controlling ocular longitudinal chromatic aberration using a spatial light modulator.
Article in Biomedical optics express, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Manipulating ocular longitudinal chromatic aberration (LCA) can enhance visual outcomes in presbyopia-correcting multifocal intraocular lenses and serve as a powerful tool for investigating eye growth mechanisms. This study introduces a spatial light modulator-based visual simulator (SLMVS) that utilizes the unique properties of diffractive optics with a negative Abbe number to precisely control ocular LCA, allowing for its correction or reversal. The system was validated through optical bench tests using a model eye and human subjects. Bench test results under polychromatic light showed improved image quality close to monochromatic performance when LCA was corrected at the far focus of both monofocal and trifocal lenses. In human tests, the SLMVS achieved a mean LCA correction of 0.01 ± 0.13 D and a mean LCA reversal of -1.62 ± 0.40 D, compared to an average ocular LCA of 1.41 ± 0.25 D.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.